TY - JOUR
T1 - Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease
T2 - A Case Series
AU - Kang, Yun Seong
AU - Moon, Hyoung Ho
AU - Lee, Seung Eun
AU - Lim, Yun Jeong
AU - Kang, Hyoun Woo
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Background: CT-P13 is the first biosimilar monoclonal antibody to infliximab. However, the antibody was tested only in rheumatoid arthritis and ankylosing spondylitis, which demonstrated equivalence to the originator in efficacy, safety, and pharmacokinetic profile. Extrapolation of its efficacy and safety to other pathologies is tenuous. Interchangeability with its originator is another unclear area. Aim: We aimed to describe the experience of CT-P13 use in inflammatory bowel disease at a tertiary center. Methods: Seventeen subjects diagnosed with Crohn’s disease (CD, n = 8) or ulcerative colitis (UC, n = 9) who were administered CT-P13 from November 2012 to October 2013 at Dongguk University Ilsan Hospital were retrospectively enrolled. Medical records analyzed included patients’ characteristics, previous history of anti-tumor necrosis factor administration, response and remission to this biosimilar antibody, disease flare-up, and adverse drug reaction. Results: Male–female ratio was 1.8. Mean age was 35.4 years (range 15–57). Mean number of CT-P13 administrations was 4.2 ± 1.9. Induction treatments were done in five UC and three CD patients. Clinical response and remission at 8 weeks were achieved in seven patients (five UC and two CD). One CD patient did not respond to CT-P13. Nine patients in maintenance with the originator were interchanged with CT-P13 (four UC and five CD patients). One UC patient experienced arthralgia and CT-P13 was discontinued. One patient experienced loss of response during the study period. Conclusions: CT-P13 may have biosimilarity and interchangeability with its originator in inflammatory bowel disease. A large, randomized, double-blind, prospective study is needed.
AB - Background: CT-P13 is the first biosimilar monoclonal antibody to infliximab. However, the antibody was tested only in rheumatoid arthritis and ankylosing spondylitis, which demonstrated equivalence to the originator in efficacy, safety, and pharmacokinetic profile. Extrapolation of its efficacy and safety to other pathologies is tenuous. Interchangeability with its originator is another unclear area. Aim: We aimed to describe the experience of CT-P13 use in inflammatory bowel disease at a tertiary center. Methods: Seventeen subjects diagnosed with Crohn’s disease (CD, n = 8) or ulcerative colitis (UC, n = 9) who were administered CT-P13 from November 2012 to October 2013 at Dongguk University Ilsan Hospital were retrospectively enrolled. Medical records analyzed included patients’ characteristics, previous history of anti-tumor necrosis factor administration, response and remission to this biosimilar antibody, disease flare-up, and adverse drug reaction. Results: Male–female ratio was 1.8. Mean age was 35.4 years (range 15–57). Mean number of CT-P13 administrations was 4.2 ± 1.9. Induction treatments were done in five UC and three CD patients. Clinical response and remission at 8 weeks were achieved in seven patients (five UC and two CD). One CD patient did not respond to CT-P13. Nine patients in maintenance with the originator were interchanged with CT-P13 (four UC and five CD patients). One UC patient experienced arthralgia and CT-P13 was discontinued. One patient experienced loss of response during the study period. Conclusions: CT-P13 may have biosimilarity and interchangeability with its originator in inflammatory bowel disease. A large, randomized, double-blind, prospective study is needed.
KW - Anti-tumor necrosis factor alpha
KW - Biosimilar
KW - Inflammatory bowel disease
KW - Infliximab
UR - http://www.scopus.com/inward/record.url?scp=84934294253&partnerID=8YFLogxK
U2 - 10.1007/s10620-014-3392-z
DO - 10.1007/s10620-014-3392-z
M3 - Article
C2 - 25326115
AN - SCOPUS:84934294253
SN - 0163-2116
VL - 60
SP - 951
EP - 956
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
IS - 4
ER -